Medical Futures to market Anesiva’s Zingo in Canada

According to the terms of the agreement, Anesiva is entitled to an undisclosed up-front payment and a fixed transfer price. Medical Futures will be responsible for all the costs associated with regulatory, distribution, marketing and selling activities.

Zingo is a single-use, needle-free system that delivers sterile lidocaine powder into the epidermis of the skin and provides topical, local analgesia.

John McLaughlin, CEO of Anesiva, said: “We are aggressively pursuing licensing agreements worldwide for Zingo with the goal of making this drug globally available in an efficient manner in order to maximize its potential market share. Our collaboration with Medical Futures’s enthusiastic and capable team lays the groundwork for expanding access to this new needle-free technology to all of North America. We continue to build upon our previously announced plans to commercialize Zingo in the US, and ultimately provide additional value to our stockholders.”